SCHEMBL3855641

SCHEMBL3855641

CCOC(=O)c1cc(OC(F)F)cc(C(=O)O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
CA12 O43570 3/20 0.47
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
CA7 P43166 3/20 0.47
CA9 Q16790 3/20 0.47
CA14 Q9ULX7 3/20 0.47
HRH3 Q9Y5N1 1/20 0.42
MRGPRX4 Q96LA9 1/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
F2 P00734 1/20 0.40
F10 P00742 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAOA P21397 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3855078 0.86 CYP2C9 (0.54) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL27893362 0.83 MRGPRX4 (0.47) CA12CA1CA2CA7CA9
SCHEMBL7234951 0.83 CYP2C19 (0.70) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL3327442 0.83 CYP2C19 (0.70) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL3853769 0.83 KDM4E (0.43) CA12CA1CA2CA7CA9
SCHEMBL29556403 0.83 KDM4E (0.43) CA12CA1CA2CA7CA9
Ammonia Solution, Strong SCHEMBL28298874 0.82 CYP2C19 (0.68) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL22660964 0.82 CYP2C19 (0.68) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL3176831 0.81 CYP2C9 (0.58) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL4328949 0.81 CYP2C19 (0.58) CYP2C9CYP2C19CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618978-B2 Amides as BACE inhibitors ELI LILLY AND COMPANY (US) 2009-11-17 US disclosed
US-7585885-B2 Pyrrolidine derivatives useful as BACE inhibitors ELI LILLY AND COMPANY (US) 2009-09-08 US disclosed
US-20070225372-A1 Amides as Bace Inhibitors ELI LILLY AND COMPANY 2007-09-27 US disclosed
US-20070213331-A1 PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS ELI LILLY AND COMPANY 2007-09-13 US disclosed
EP-1740575-A2 PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2007-01-10 EP disclosed
EP-1740573-A1 AMIDES AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2007-01-10 EP disclosed
WO-2005108358-A2 PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2005-11-17 WO disclosed
WO-2005108391-A1 AMIDES AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225372-A1 Amides as Bace Inhibitors BACE2, BACE1, APP CYP2C9 999/4885CYP2C19 951/4885CA12 330/4885
US-20070213331-A1 PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS BACE1, BACE2, PSEN1 CYP2C9 1765/4885CYP2C19 1109/4885CA12 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.